Pharmacogenomics Biomarkers of Soft Tissue Sarcoma Therapies
Soft tissue sarcomas (STS) are heterogeneous rare malignancies comprising ~1% of all solid cancers in adults and including more than 70 histological and molecular subtypes with different pathological and clinical development characteristics. Over the last two decades, the increased knowledge of the...
Main Authors: | Chiara Caruso, Cecilia Garofalo |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.00509/full |
Similar Items
-
The Role of Plastic Reconstructive Surgery in Surgical Therapy of Soft Tissue Sarcomas
by: Rebekka Götzl, et al.
Published: (2020-11-01) -
Recent Advances in the Treatment of Metastatic Soft Tissue Sarcoma
by: Elizabeth J. Davis, et al.
Published: (2018-12-01) -
Exome-Wide Analysis of the DiscovEHR Cohort Reveals Novel Candidate Pharmacogenomic Variants for Clinical Pharmacogenomics
by: Maria-Theodora Pandi, et al.
Published: (2020-05-01) -
The role of Pazopanib in Soft Tissue Sarcoma: A comprehensive review of the literature
by: Fotopoulos George, et al.
Published: (2015-09-01) -
Soft tissue sarcomas: Evaluation by immunohistochemistry
by: Ibtisam Hussein Al Obaidi
Published: (2020-06-01)